| Identification | Back Directory | [Name]
bremazocine | [CAS]
75684-07-0 | [Synonyms]
2-(1-Hydroxy-cyclopropylmethyl)-5-ethyl-9,9-dimethyl-2'-hydroxy-6,7-benzomorphan
2,6-Methano-3-benzazocin-8-ol, 6-ethyl-1,2,3,4,5,6-hexahydro-3-((1-hydroxycyclopropyl)methyl)-11,11-dimethyl-, (2R)-
[2R,(-)]-6-Ethyl-1,2,3,4,5,6-hexahydro-3-[(1-hydroxycyclopropyl)methyl]-11,11-dimethyl-2,6-methano-3-benzazocin-8-ol | [Molecular Formula]
C20H29NO2 | [MDL Number]
MFCD32220470 | [MOL File]
75684-07-0.mol | [Molecular Weight]
315.45 |
| Hazard Information | Back Directory | [Description]
Bremazocineis a potent, log-acting opiate kappa-agonist & centrally acting analgesic. | [Uses]
Bremazocine is a potent opioid kappa receptor agonist with analgesic activity. Bremazocine induces peripheral analgesia by releasing endogenous norepinephrine. The analgesic effect of bremazocine is associated with interaction with adenosine receptors. Bremazocine produces a dose-dependent peripheral analgesia after topical application. The effect of bremazocine is affected by nonselective α(2) adrenaline receptor antagonists, suggesting that it acts through a norepinephrine pathway[1]. | [Definition]
ChEBI: Bremazocine is a benzazocine. | [References]
[1] Mu, delta, and kappa opioid receptor agonists induce peripheral antinociception by activation of endogenous noradrenergic system |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|